reviewTop 1% cited

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

Journal of Antimicrobial Chemotherapy · 2005 · Vol. 55(3) · pp. 283–288

Judith N. Steenbergen✉(Cubist Pharmaceuticals (United States))Jeff Alder(Cubist Pharmaceuticals (United States))Grace M. Thorne(Cubist Pharmaceuticals (United States))Francis P. Tally(Cubist Pharmaceuticals (United States))

View via DOI Publisher page

Abstract

Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant <I>Staphylococcus aureus</I>, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.

Antimicrobial Resistance in Staphylococcus Bacterial Identification and Susceptibility Testing Antibiotic Resistance in BacteriaDaptomycinLipopeptideAntibioticsMicrobiologyStaphylococcus aureusAntimicrobialVancomycinMedicineGramBiology

Citations

559

FWCI

13.12

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by